RxDoctor Payments Data

Rani Kapur-Pado, DO

Cardiovascular Disease · Sidney, NYNPI 1801908553

Payments from drug & device makers

$1,167in general payments, 2019–2025

Across 64 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$279
  • Boehringer Ingelheim$250
  • Johnson & Johnson$139
  • Novartis$117
  • AstraZeneca$93
  • Amarin Pharma, Inc.$58
  • plus $232 from 8 others

What the payments were for

  • Food & beverage$1,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,167 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$61,493
Medicare patients
87
Services billed
1,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$119,794
OzempicSemaglutide91$104,383
JanuviaSitagliptin Phosphate61$69,703
TrulicityDulaglutide55$54,493
XareltoRivaroxaban31$27,481
ProliaDenosumab15$26,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$23,757
JardianceEmpagliflozin14$21,064
EntrestoSacubitril/Valsartan16$17,048
MounjaroTirzepatide13$16,379
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$15,483
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$12,171
Breo ElliptaFluticasone/Vilanterol26$11,916
Combivent RespimatIpratropium/Albuterol Sulfate17$10,524
SymbicortBudesonide/Formoterol Fumarate20$9,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$119,79492 claims
Novo NordiskOzempic$50$104,38391 claims
MerckJanuvia, Belsomra$279$76,05375 claims
Lilly USA, LLCTrulicity, Mounjaro$30$70,87268 claims
Boehringer IngelheimJardiance, Combivent Respimat$250$31,58831 claims
Johnson & JohnsonXarelto$139$27,48131 claims
AmgenProlia$39$26,08315 claims
NovartisEntresto$117$17,04816 claims
AstraZenecaSymbicort$93$9,22620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Sidney

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →